8-K: DiaMedica Therapeutics Announces Full Year 2023 Financial Results and Business Update

DiaMedica Therapeutics reported its full year 2023 financial results, provided a business update, and announced the commencement of ReMEDy2 clinical site activation.

Summary

• DiaMedica Therapeutics announced its full year 2023 financial results, reporting a net loss of $19.38 million, compared to a net loss of $13.68 million in 2022.
• The company's research and development expenses increased to $13.1 million in 2023 from $7.8 million in 2022, driven by costs related to the ReMEDy2 trial and DM199 development.
• General and administrative expenses also rose to $8.2 million in 2023 from $6.2 million in 2022, due to increased legal fees and personnel costs.
• DiaMedica's cash, cash equivalents, and investments totaled $52.9 million as of December 31, 2023, with a working capital of $50.9 million.
• The company's cash runway is projected to extend into 2026.
• The ReMEDy2 clinical trial has commenced site activation in the US in December 2023, with six sites opened as of the press release date.
• The majority of US sites are expected to be activated by the third quarter of 2024, with Canadian and Australian site activations expected to begin in the third and fourth quarters of 2024, respectively.
• The company has modified the ReMEDy2 protocol to focus on patients with moderate acute ischemic strokes (AIS) with a NIHSS score of 5-15.
• Full enrollment for the 144 patients for the interim analysis is expected to be completed in the first quarter of 2025.
• Dr. Lorianne Masuoka joined DiaMedica as Chief Medical Officer in January 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has a strong cash position and is making progress with its clinical trial, the increased losses and expenses are concerning. The sentiment is neutral to slightly negative.

Positives

• The company has a strong cash position of $52.9 million, providing a cash runway into 2026.
• ReMEDy2 clinical trial site activation has commenced, with six sites already opened in the US.
• The company has strengthened its management team with the appointment of Dr. Lorianne Masuoka as Chief Medical Officer.
• The ReMEDy2 trial protocol modification is expected to increase the probability of clinical success.
• The company has received provisional endorsement from the Australian Stroke Trials Network (ASTN) for site activation in Australia.
• The company is expanding the ReMEDy2 trial into the United Kingdom and Europe.

Negatives

• The company reported a net loss of $19.38 million for the year ended December 31, 2023, which is an increase from the $13.68 million loss in 2022.
• Research and development expenses increased to $13.1 million in 2023, up from $7.8 million in 2022.
• General and administrative expenses increased to $8.2 million in 2023, up from $6.2 million in 2022.
• Net cash used in operating activities increased to $18.7 million in 2023 from $11.5 million in 2022.

Risks

• The company's clinical trials may not be successful, and the results may not be predictive of future outcomes.
• The company may face challenges in enrolling patients in the ReMEDy2 trial within the anticipated timeframes.
• The company's ability to obtain regulatory approvals for DM199 is not guaranteed.
• The company relies on third parties to conduct clinical trials, which could pose risks.
• The company may need to raise additional capital to fund its operations and clinical trials.
• The company is subject to risks related to the COVID-19 pandemic, hospital staffing shortages, and global supply chain issues.

Future Outlook

DiaMedica expects its R&D expenses to increase moderately as the ReMEDy2 trial expands globally, while G&A costs are expected to remain steady or decline slightly. The company anticipates full enrollment for the interim analysis of the ReMEDy2 trial in the first quarter of 2025 and has a cash runway into 2026.

Management Comments

• We have been focused on engaging and activating high-quality stroke centers to set the foundation for patient enrollment, commented Dr. Masuoka.
• We are encouraged by the level of interest from quality study sites and are committed to bringing DM199 to stroke patients.

Industry Context

DiaMedica is developing DM199, a recombinant form of human tissue kallikrein-1 (rKLK1), for the treatment of acute ischemic stroke (AIS). This is a significant area of unmet medical need, as current treatment options are limited, particularly for moderate strokes. The company's focus on moderate strokes aligns with the approach taken by Shanghai Pharmaceuticals in China with their urinary-derived KLK1 product, KAILIKANG. The company is also expanding its clinical trial globally, which is a common strategy for biopharmaceutical companies seeking to bring new treatments to market.

Comparison to Industry Standards

• DiaMedica's focus on moderate AIS patients aligns with Shanghai Pharmaceuticals' approach with KAILIKANG in China, suggesting a validated patient population for KLK1-based therapies.
• The company's cash runway into 2026 is a positive sign, as many clinical-stage biopharma companies face funding challenges.
• The increase in R&D expenses is typical for a company advancing a clinical program, but the increase in G&A expenses is worth monitoring.
• The company's net loss is consistent with other clinical-stage biopharma companies that are investing heavily in research and development.
• The company's strategy of expanding the ReMEDy2 trial globally is similar to other companies seeking to gain regulatory approvals in multiple regions.
• The company's focus on a specific patient population (moderate AIS) is a common strategy to improve the probability of clinical success.

Management Changes

Legal Proceedings

• The company incurred increased legal fees in connection with its lawsuit against Pharmaceutical Research Associates Group B.V. (PRA Netherlands).

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and expenses.
• Employees may be impacted by the expansion of the clinical team and the company's growth.
• Patients with acute ischemic stroke may benefit from the development of DM199.
• Suppliers and creditors may be impacted by the company's financial performance.

Next Steps

• Continue activating clinical sites for the ReMEDy2 trial in the US, Canada, and Australia.
• Expand the ReMEDy2 trial into the United Kingdom and Europe.
• Complete full enrollment for the 144 patients for the interim analysis of the ReMEDy2 trial by the first quarter of 2025.
• Continue to develop DM199 for the treatment of acute ischemic stroke.

Key Dates

Keywords

DiaMedica Therapeutics, DM199, Acute Ischemic Stroke, ReMEDy2, Clinical Trial, rKLK1, Neurological Disorders, Cardio-Renal Disease, Biopharmaceutical, Financial Results